Innovative Solutions to Meet the Complex Pharmaceutical Supply Challenges
AVAILABLE ON-DEMAND

Event link to be sent with confirmation

Event Details:

Co-organized with Bionow, this webinar explores how dosage form selection can shape future decisions and project trajectory of product development, and how working with a single integrated provider can streamline product development, reduce the risk of avoidable delays, and shorten time to clinic. 

Agenda: 

Get from Concept to Clinic Faster on the Product Development Superhighway 

  • Identify opportunities to streamline product development and shorten timelines 
  • Understand how dosage form selection can shape future decisions and project trajectory 
  • Understand the pros and cons of working with a single integrated provider 

Optimizing Clinical Study Management 

  • Efficient coordination of clinical supplies 
  • Clinical manufacturing, packaging, storage and distribution 
  • Integrated approach from development to clinical and benefits to using one vendor 




FEATURED SPEAKERS
Stephen Tindal
Director, Science & Technology, Catalent

Mr. Tindal is part of Catalent’s Science and Technology Team where he leads the technical support in Europe. He has worked at Catalent for 34 years and has held leadership positions in Formulation Development, Process Development and both Clinical and Commercial Operations at FDA & EMA regulated facilities. 

Gavin Yates 
Program Director, Clinical Supply Services & Drug Product Technologies Integrations, Catalent 

Mr. Yates has more than 15 years’ experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. 

By submitting this form you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy | Privacy Shield Statement.